Business context and reporting period
The supplied filing is MedTech Acquisition Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2021—not a filing identified as Trisalus Life Sciences, Inc. MedTech was a shell company formed to pursue a business combination and had not begun operating or generating revenue. The quarter’s activities related primarily to the company’s formation, public offering and search for a target.
Financial results and position
- Revenue: No operating revenue. The company reported $34,624 of trust-account interest income.
- Results: Operating and formation costs were $307,992; a $98,666 warrant fair-value expense was partly offset by interest income, resulting in a net loss of $372,034. Loss per non-redeemable Class B share was $0.06. Margins are not meaningful for this pre-combination shell company.
- Cash flow: Cash used in operating activities was $205,848. Cash outside the trust account fell from $1,334,998 at December 31, 2020 to $1,129,150 at March 31, 2021.
- Liquidity: Working capital was approximately $1.6 million. The trust account held $250,037,922, principally for a business combination or public-share redemptions. Management believed available working capital and potential borrowing capacity would cover needs through a business combination or one year from the filing. Sponsor or affiliate working-capital loans were optional, and none were outstanding.
- Debt and obligations: No long-term debt was reported. Liabilities included $160,010 of accrued expenses, $14,741,332 of warrant liabilities and $8.75 million of deferred underwriting fees, payable only if a business combination is completed. Monthly sponsor administrative fees were $10,000.
- Balance sheet: Total assets were $251.8 million; total liabilities were $23.7 million. Class A shares subject to possible redemption were presented as $223.1 million of temporary equity.
Changes versus the prior comparable period
The filing provides no prior-year-quarter income-statement or cash-flow comparison. Against December 31, 2020, operating cash declined by about $206,000; trust assets rose by about $35,000; warrant liabilities increased by about $99,000; and accrued expenses increased by about $57,000. The trust’s U.S. Treasury securities matured during the quarter, leaving substantially all trust assets in cash at March 31.
Outlook, risks and unusual items
- The company had until December 22, 2022 to complete a business combination; otherwise, it generally must redeem public shares and liquidate. There was no assurance it would complete a transaction.
- Management expected to use funds outside the trust account for target identification, due diligence and transaction costs. It said additional financing might be needed if costs exceeded estimates or redemptions were significant.
- The filing says the company’s financial statements were restated to classify derivative warrants as liabilities. Management identified a material weakness related to that restatement and concluded disclosure controls and procedures were not effective. Planned remediation included improved accounting research resources and communication, but the company gave no assurance these steps would be effective.
- Management said COVID-19 could adversely affect the company’s financial position, results or target search, but the specific impact was not determinable. The filing reported no legal proceedings and no material changes to previously disclosed risk factors.
- Warrant liabilities were measured at fair value and remeasured each reporting period, creating earnings volatility. Warrants could expire worthless if no business combination is completed.
Important facts for investors to verify
- Confirm the registrant and filing match the intended company: this document names MedTech Acquisition Corporation, not Trisalus Life Sciences, Inc.
- Review the June 28, 2021 Form 10-K/A and restatement details, including the warrant accounting and the material weakness remediation.
- Distinguish the $250.0 million trust balance from the approximately $1.1 million of operating cash available outside the trust.
- Check subsequent filings for business-combination developments, redemption levels, financing needs and any changes to the December 22, 2022 deadline.